Talphera (TLPH) Competitors

In the previous week, Anthem's average media sentiment score of 0.00 equaled Talphera'saverage media sentiment score.

90.5% of Anthem shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 22.6% of Anthem shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Talphera has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Anthem has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market. Comparatively, Talphera has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 92.31%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 177.78%. Given Talphera's higher possible upside, analysts clearly believe Talphera is more favorable than Anthem.

Anthem's return on equity of -53.52% beat Talphera's return on equity.

37.7% of Talphera shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 8.6% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Talphera has higher earnings, but lower revenue than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

In the previous week, Alpha Cognition had 5 more articles in the media than Talphera. MarketBeat recorded 5 mentions for Alpha Cognition and 0 mentions for Talphera. Alpha Cognition's average media sentiment score of 0.49 beat Talphera's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media.

Talphera has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market.

Talphera has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Alpha Cognition's return on equity of -54.60% beat Talphera's return on equity.

Talphera presently has a consensus target price of $3.00, indicating a potential upside of 177.78%. Alpha Cognition has a consensus target price of $18.00, indicating a potential upside of 99.12%. Given Talphera's higher probable upside, research analysts clearly believe Talphera is more favorable than Alpha Cognition.

37.7% of Talphera shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Zentalis Pharmaceuticals had 10 more articles in the media than Talphera. MarketBeat recorded 10 mentions for Zentalis Pharmaceuticals and 0 mentions for Talphera. Zentalis Pharmaceuticals' average media sentiment score of 0.30 beat Talphera's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Talphera has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Talphera is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Talphera currently has a consensus price target of $3.00, indicating a potential upside of 177.78%. Zentalis Pharmaceuticals has a consensus price target of $7.50, indicating a potential upside of 198.80%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Talphera.

Talphera has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

Zentalis Pharmaceuticals' return on equity of -70.18% beat Talphera's return on equity.

Journey Medical has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Talphera has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Journey Medical has higher revenue and earnings than Talphera. Journey Medical is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

In the previous week, Journey Medical had 4 more articles in the media than Talphera. MarketBeat recorded 4 mentions for Journey Medical and 0 mentions for Talphera. Journey Medical's average media sentiment score of 0.42 beat Talphera's score of 0.00 indicating that Journey Medical is being referred to more favorably in the media.

Journey Medical currently has a consensus target price of $14.00, suggesting a potential upside of 135.29%. Talphera has a consensus target price of $3.00, suggesting a potential upside of 177.78%. Given Talphera's higher possible upside, analysts plainly believe Talphera is more favorable than Journey Medical.

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 14.5% of Journey Medical shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Talphera has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Talphera's return on equity.